Stay updated on Nivolumab for ALK+ ALCL: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.
Latest updates to the Nivolumab for ALK+ ALCL: Clinical Trial page
- Check3 days agoChange DetectedThe new screenshot appears to replicate the study record with formatting adjustments only; core content such as the study title, design, eligibility criteria, interventions, endpoints, and locations is unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check10 days agoNo Change Detected
- Check32 days agoChange DetectedUpdated core content with a government funding notice and NIH Clinical Center operating status, and bumped software version from v3.1.0 to v3.2.0.SummaryDifference3%
- Check39 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0. This is an incremental update to the page metadata; no user-facing content changes detected.SummaryDifference0.1%
- Check53 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%
- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%
- Check67 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as detailed information on various antibodies and proteins. However, many specific disease-related terms and drug information have been removed.SummaryDifference4%
Stay in the know with updates to Nivolumab for ALK+ ALCL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.